PDCD1 and neoplasm: The authors also performed a preclinical trial in mice challenged with NY-ESO-1-expressing cancer cells, observing that, although single-agent nanovaccines or anti-PD-1 antibodies were poor or not effective, tumor growth was inhibited in animals treated with a combination of the two.